Results 11 to 20 of about 24,787 (310)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]

, 2020
Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C, Lopes, A, Lopes, C, Sokolova, A   +3 more
core   +1 more source

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

Journal of Allergy and Clinical Immunology: Global, 2023
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD, Takaaki Itonaga, MD, Makoto Nishino, MD, Noriyuki Yanagida, MD, PhD, Sakura Sato, MD, Motohiro Ebisawa, MD, PhD   +5 more
doaj   +1 more source

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

BMC Pulmonary Medicine, 2022
Background Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. Methods We retrospectively
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, Shota Fujimoto, Junko Watanabe, Hiromichi Hara, Takanori Numata, Kazuyoshi Kuwano, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]

, 2020
Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos, Baldrich, Esther Serra, Herráez, L., Jáuregui, Ignacio, Martín-Santiago, Ana, Ortiz de Frutos, Javier, Sastre, Joaquin, Silvestre, Juan Francisco, Universitat Autònoma de Barcelona, Valero, Antonio   +9 more
core   +3 more sources

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults

Качественная клиническая практика, 2022
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin, Y. M. Gomon, M. A. Proskurin, Y. E. Balikina   +3 more
doaj   +1 more source

Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)

International Journal of Women's Dermatology, 2019
Background: The mechanisms underlying eye-related complications with dupilumab are poorly understood. Objective: This study aimed to determine the incidence and characteristics of ocular complications with dupilumab and the prevalence of comorbid ...
Jodie Raffi, BA, Raagini Suresh, BS, Harvey Fishman, MD, PhD, Nina Botto, MD, Jenny E. Murase, MD   +4 more
doaj   +1 more source

Two‐sided influence of dupilumab on alopecia areata co‐existing with severe atopic dermatitis: A case series and literature review

Journal of Cutaneous Immunology and Allergy, 2023
Objectives Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA ...
Masahiro Fukuyama, Misaki Kinoshita‐Ise, Yoshiko Mizukawa, Manabu Ohyama   +3 more
doaj   +1 more source

Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy.
Gavin Li, Meghan Berkenstock, Uri Soiberman   +2 more
doaj   +1 more source